Vaccinex to develop antibody to suppress autoimmune response
Submitted by art on Mon, 2007-03-12 06:38.
Vaccinex, Inc. announced that it has entered into a collaboration with Teva Pharmaceutical Industries Ltd. to develop and commercialize VX15, a novel human antibody discovered by Vaccinex. VX15 represents a new targeted therapy that has the potential to improve efficacy in treating Multiple Sclerosis by both suppressing the body's autoimmune response and blocking damage to the central nervous system.